Clinical trials: BA - Biliary Atresia
Biliary Atresia
Mapping Disease Pathways for Biliary Atresia
This project will primarily evaluate the developmental/genetic basis of biliary atresia, the most common cause of liver failure at birth, and which accounts of half of all liver transplants performed worldwide in children.
- Trial name
- BA (NCT03273049)
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- University of Pittsburgh
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Biliary Atresia
Pentoxifylline Therapy in Biliary Atresia
The purpose of this study is to determine whether pentoxifylline reduces liver damage in infants with biliary atresia.
- Trial name
- NCT01774487
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Baylor College of Medicine
Biliary Atresia
Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia
Biliary atresia is a rare, progressive liver disease that only affects infants. It leads to complete obstruction and scarring of the bile duct. Current non-invasive diagnostic tests have limited sensitivity.
- Trial name
- NCT07513038
- Testing
- Indocyanine Green (ICG)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Boston Children's Hospital
Stool Color Card, Biliary Atresia
Stool Card in Biliary Atresia
To evaluate the effectiveness of using a stool color card as a non-invasive screening tool for the early detection of biliary atresia, with the objective of improving early diagnosis rates and facilitating timely surgical…
- Trial name
- NCT07139717
- Volunteers
- 100 people
- Sponsor
- Assiut University
Biliary Atresia
Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
A study to evaluate the efficacy and safety of maralixibat in infants with Biliary Atresia (BA) after Hepatoportoenterostomy (HPE, also known as the Kasai procedure).
- Trial name
- EMBARK (NCT04524390)
- Testing
- Maralixibat
- Where
- 22 sites in United States, China and 6 more
- Volunteers
- 75 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Biliary Atresia
GCSF Adjunct Therapy for Biliary Atresia
The Investigators propose to test the hypothesis that GCSF therapy enhances the clinical outcome of Kasai operated Biliary Atresia (BA) patients.
- Trial name
- BA_GCSF (NCT03395028)
- Testing
- Granulocyte Colony-Stimulating Factor
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 6 people
- Sponsor
- Holterman, Ai-Xuan, M.D.
Biliary Atresia, Cholangitis
Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
This study is non-inferiority trial design. This study aimed to investigate the effect of prophylactic oral antibiotics on preventing cholangitis in biliary atresia (BA) patients after Kasai portoenterostomy (KP) by comparing the…
- Conditions
- Biliary Atresia, Cholangitis, Anti-Bacterial Agents
- Trial name
- NCT05925309
- Testing
- Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem, Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor
- Where
- China
- Volunteers
- 356 people
- Sponsor
- Children's Hospital of Fudan University
Cholestasis in Newborn Infant, Biliary Atresia
Dry Blood Spot Screening Test for Neonatal Cholestasis Patients
Cholestatic jaundice with multitude of causes affects approximately 1 in every 2,500 infants. Of the many conditions that cause neonatal cholestasis, the most commonly identifiable are biliary atresia (BA) (25%-35%).
- Trial name
- DBS-SCReNC (NCT03667534)
- Testing
- Dry blood spot screening
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Biliary Atresia, Cognitive Impairment
BILACO Trial: Biliary Atresia - a Severe Complex Congenital Liver Disease
Biliary atresia is the most severe form of cholestatic liver disease. The children have high morbidity and mortality and get devastating pruritus and fatigue, failure to thrive, progressive hepatic failure and impaired…
- Trial name
- BILACO (NCT05399745)
- Testing
- Neurocognitive monitoring
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Nutrition Disorder, Infant, Biliary Atresia
Nutritional Intervention for Biliary Atresia
Infants with biliary atresia (Biliary atresia, BA) have an increased risk of malnutrition due to insufficient dietary intake to maintain normal growth, impaired intestinal absorption, increased metabolic rate, and damage to some…
- Trial name
- NCT06764082
- Testing
- high MCT formula, normal oral intake of the traditional formula
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tongji Hospital
Biliary Atresia
Early Predictors for the Short Term Native Liver Survival in Patients With Biliary Atresia After Kasai Procedure
Many factors have been proven that may affect NLS in BA patients after KP;however,the early predictors for NLS were not be finally detected.This study was designed to evaluate and identify the preoperative and early postoperative…
- Trial name
- NCT05909033
- Testing
- Kasai procedure
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Weibing Tang
Primary Sclerosing Cholangitis, Biliary Atresia
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism.
- Trial name
- NCT02137668
- Testing
- Oral Vancomycin
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sacramento Pediatric Gastroenterology
Biliary Atresia, Neonatal Cholestasis
Development and Validation of a Screening Score for the Biliary Atresia in Infantile Cholestasis: A Prospective Study
Better survival and prognosis of biliary atresia (BA) depend on early diagnosis and timely Kasai portoenterostomy. Identifying BA from other causes of infantile cholestasis at early stage of the disease still remains a major…
- Conditions
- Biliary Atresia, Neonatal Cholestasis, Infantile Hepatitis Syndrome
- Trial name
- NCT03842150
- Testing
- biliary atresia screen score
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Portal Hypertension, Biliary Atresia
Primary Prophylaxis for Variceal Bleed in Biliary Atresia
Biliary atresia is the commonest etiology of neonatal cholestasis and is the most common indication for pediatric liver transplantation world-wide.
- Trial name
- BA-BB (NCT04494763)
- Testing
- Propanolol
- Where
- India
- Volunteers
- 92 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Biliary Atresia
Biliary Atresia Research Network Northeast
This is a multi-center retrospective chart review to compile a data repository of the management and outcomes of children with biliary atresia.
- Trial name
- BARNN (NCT06184971)
- Where
- 14 sites in United States
- Volunteers
- 320 people
- Sponsor
- Yale University
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to…
- Trial name
- NCT06553768
- Testing
- Maralixibat
- Where
- 23 sites in United States, Brazil and 8 more
- Volunteers
- 90 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Biliary Atresia
Laparoscopic Kasai Has Similar Anesthetic Outcomes to Open Kasai
Biliary atresia (BA) is a rare biliary tree disease with a high incidence in eastern Asia. Kasai operation is a standard treatment for BA, and studies have shown that timely Kasai operation is crucial for better outcomes.
- Trial name
- NCT06163417
- Testing
- laparoscopic
- Volunteers
- 28 people
- Sponsor
- Taichung Veterans General Hospital
Dental Diseases
Dental Dyschromia and Quality of Life in Early Prolonged Hyperbilirubinemia
The main objective of this study is to assess the prevalence of dental discoloration (dental dyschromia) in children who experienced high levels of bilirubin in their blood (hyperbilirubinemia) during their early years.
- Trial name
- SMILE (NCT06506734)
- Testing
- Questionnaires
- Where
- 9 sites in France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Toulouse
Biliary Atresia
Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia
The Children Liver Disease Research and Education Network (ChiLDREN) is conducting a clinical trial to determine the feasibility, acceptability, tolerability and safety profile of IVIG treatment administered to infants after…
- Trial name
- PRIME (NCT01854827)
- Testing
- Intravenous immunoglobulin (IVIG)
- Where
- 7 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)